BiotechTube

AboBoNT-A + OnaBoNT-A

ApprovedCompleted
0 watching 0 views this week🔥 Hot
82
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Upper Limb Spasticity

Conditions

Upper Limb Spasticity

Trial Timeline

Jun 23, 2021 → Aug 26, 2025

NCT ID
NCT04936542

About AboBoNT-A + OnaBoNT-A

AboBoNT-A + OnaBoNT-A is a approved stage product being developed by Ipsen for Upper Limb Spasticity. The current trial status is completed. This product is registered under clinical trial identifier NCT04936542. Target conditions include Upper Limb Spasticity.

Hype Score Breakdown

Clinical
30
Activity
20
Company
7
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT04936542ApprovedCompleted

Competing Products

20 competing products in Upper Limb Spasticity

See all competitors
ProductCompanyStageHype Score
Nivolumab 100 MG in 10 ML InjectionOno PharmaceuticalPhase 2
52
Remimazolam TosilateJiangsu Hengrui MedicineApproved
85
ABBV-950 + BOTOX + Placebo for ABBV-950AbbViePhase 1
33
BOTOX + Placebo for BOTOXAbbViePhase 2
52
BOTOXAbbVieApproved
85
MK-3475 and BCGMerckPhase 2
52
Montelukast + PlaceboMerckApproved
85
Muntelukast + PlaceboMerckPhase 3
77
IFF flavor 316 282, Paracetamol, PseudoephedrineNovartisPhase 3
77
Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets + Paracetamol (500 mg) tabletsNovartisPhase 3
77
diclofenac potassium + nimesulideNovartisApproved
85
Diclofenac gelNovartisApproved
85
IFF flavor 316 282, Paracetamol , Phenylephrine, GuaifenesinNovartisPhase 3
77
Domvanalimab + Zimberelimab + Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin + NivolumabGilead SciencesPhase 3
76
Azithromycin SRPfizerPhase 3
76
NivolumabBristol Myers SquibbPre-clinical
22
NivolumabBristol Myers SquibbPre-clinical
22
REGN475/SAR164877 + Placebo (for REGN475/SAR164877)Regeneron PharmaceuticalsPhase 2
51
IPN10200 + IPN10200 Placebo + DysportIpsenPhase 1/2
38
Botulinum toxin type AIpsenPhase 3
74

Other Products from Ipsen

AbobotulinumtoxinA + PlaceboApproved
82
lanreotide acetateApproved
82
Tigan® + PlaceboApproved
82
Diosmectite (Smecta®)Approved
82
lanreotide (Autogel formulation)Approved
82